




PHARMACEUTICAL 2022

Cartesian Therapeutics Inc.
Rank 359 of 466





RealRate

PHARMACEUTICAL 2022

Cartesian Therapeutics Inc. Rank 359 of 466



The relative strengths and weaknesses of Cartesian Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cartesian Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Cartesian Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 8.8%, being 69% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	144,443
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	72,251
Liabilities, Non-Current	20,015
Other Assets	13,298
Other Compr. Net Income	-3.0
Other Expenses	21,149
Other Liabilities	45,096
Other Net Income	59
Other Revenues	85,077
Property and Equipment	2,142
Research and Development	68,736
Selling, General and Administrative Expense	20,938

Output Variable	Value in 1000 USD
Assets	159,883
Liabilities	137,362
Expenses	110,823
Revenues	85,077
Stockholders Equity	22,521
Net Income	-25,687
Comprehensive Net Income	-25,688
Economic Capital Ratio	8.8%